These included four colorectal cancer patients (two with KRAS G12V, one with KRAS Q61L, one with NRAS G61K; patients #18, #28, #79 and #21; Supplementary Table 1) and one non-small cell lung cancer patient with no targetable mutations (patient #29). This evidence concerns the gene KRAS and colorectal cancer.